Best GLP-1 for Insulin Resistance: 5 Ranked for 2026
Best Overall
Best GLP-1 for insulin resistance overall: tirzepatide — Zepbound if you don’t have type 2 diabetes, or Mounjaro if you do. Across head-to-head comparisons including SURPASS-2 and SURMOUNT-5 (20.2% vs 13.7% mean weight loss at 72 weeks), tirzepatide has consistently produced greater improvements in both insulin-sensitivity markers and weight reduction. The detail that matters most: in a Phase 2b analysis, weight loss explained only 13–21% of the improvement in HOMA-IR — meaning most of tirzepatide’s insulin-sensitizing effect operates through pathways beyond weight loss alone.
Choose semaglutide if your priority is the deepest cardiovascular, kidney, or fatty-liver label support. Choose Foundayo or oral Wegovy if needles are what’s stopping you from starting.
No GLP-1 is FDA-approved for “insulin resistance” alone — but most adults with insulin resistance qualify through obesity, overweight-with-comorbidity, or type 2 diabetes pathways. The right medication is the one you can realistically qualify for, afford, and stay on.
Answer a few questions — get a personalized recommendation based on your situation
Jump to: Rankings table · By situation · Tirz vs sema · Oral options · Without diabetes · FDA vs compounded · 2026 pricing · Do you have IR? · FAQ
The RX Index Insulin Resistance Fit Score: 5 GLP-1 Medications Ranked
We built this ranking because no page on the internet combines insulin-resistance efficacy data, organ-protection labels, delivery format, and real 2026 pricing in one place. To assemble what you see below, we pulled from the SURPASS-2 and SURMOUNT-5 trials (NEJM), three JCEM post-hoc analyses, the SURMOUNT-1 three-year extension, the ATTAIN Phase 3 program, the Vanderbilt liraglutide study, current FDA labels, and manufacturer pricing pages — all verified the week of April 7, 2026.
| Rank | Medication | Receptor target | IR Fit Score | Avg weight loss | Delivery | Best for | 2026 self-pay start |
|---|---|---|---|---|---|---|---|
| #1 | Tirzepatide (Zepbound / Mounjaro) | GLP-1 + GIP dual | 89/100 | 20.2%¹ | Weekly injection | Prediabetes, visceral fat, strongest metabolic push | $299 (2.5 mg vials)² |
| #2 | Semaglutide injection (Wegovy / Ozempic) | GLP-1 only | 84/100 | 13.7–16.9%³ | Weekly injection | Heart disease risk, CKD, MASH/fatty liver | $199 intro⁴ |
| #3 | Oral Wegovy (semaglutide tablets) | GLP-1 only | 79/100 | 16.6%⁵ | Daily pill (empty stomach) | Strongest oral evidence, no needles | $149 (low dose)⁶ |
| #4 | Foundayo (orforglipron) | GLP-1 only (non-peptide) | 74/100 | 12.4%⁷ | Daily pill (any time, no restrictions) | Easiest oral routine, needle-averse | $149 (0.8 mg)⁸ |
| #5 | Liraglutide (Saxenda / Victoza) | GLP-1 only | 58/100 | 5–8%⁹ | Daily injection | Legacy coverage situations only | $372+ with coupons |
¹ SURMOUNT-5: tirzepatide vs semaglutide in adults with obesity, 72 weeks, on-treatment estimand (NEJM, 2025). ² Zepbound self-pay vials start at $299/mo for 2.5 mg; higher doses $399–$449/mo (Lilly, April 2026).
³ SURMOUNT-5 semaglutide arm: 13.7% at 72 weeks; STEP 1: 16.9% at 68 weeks (different trial, different population). ⁴ Wegovy NovoCare intro; ongoing self-pay $349+/mo.
⁵ OASIS 4: oral semaglutide 25 mg, 68 weeks (Novo Nordisk). ⁶ Oral Wegovy starts at $149 for 1.5–4 mg; maintenance dose (25 mg) is $299/mo.
⁷ ATTAIN-1: orforglipron highest dose, on-treatment estimand, 72 weeks (Lilly reports 12.4% on-treatment, 11.1% regardless of trial completion). ⁸ Foundayo starts at $149/mo for 0.8 mg; higher doses $199–$299/mo (Ro pricing, April 2026). ⁹ Various liraglutide trials across different populations and durations.
Get started for $39, then as low as $74/mo with annual plan. FDA-approved tirzepatide.
Which GLP-1 Should You Choose for Your Specific Situation?
The best GLP-1 for insulin resistance depends on what’s driving your insulin resistance, what other health concerns you’re managing, and what you’re willing to do every week. Find your situation below.
Prediabetes, visceral fat, or the “doing everything right” plateau → Tirzepatide
This is the profile tirzepatide was practically built for. You’ve been told your fasting insulin is high, your A1C is creeping toward 5.7–6.4%, your waist won’t shrink despite consistent effort, and metformin alone hasn’t been enough.
The SURMOUNT-1 three-year extension is the data point that matters most here: 94% reduction in progression from prediabetes to type 2 diabetes. That’s tirzepatide’s dual receptor mechanism doing work that a pure GLP-1 agonist can’t fully replicate. For readers with elevated HOMA-IR, tirzepatide’s improvement in insulin sensitivity operates substantially through weight-loss-independent pathways — meaning it’s doing more than just making you lighter.
Access paths: Zepbound (if weight management is the indication) or Mounjaro (if type 2 diabetes). Self-pay via LillyDirect starts at $299/mo. Through Ro with insurance support.
Get started for $39, then as low as $74/mo with annual plan.
Heart disease risk, CKD, or fatty liver (MASH) alongside insulin resistance → Semaglutide
Semaglutide loses to tirzepatide on raw metabolic power, but it wins on something that may matter more for your specific situation: organ-level proof. Wegovy holds an FDA-approved indication for reducing cardiovascular risk in adults with established cardiovascular disease and obesity or overweight — the first GLP-1 to earn that label. Ozempic carries an FDA-approved indication tied to type 2 diabetes plus chronic kidney disease. And Wegovy’s label now includes noncirrhotic MASH with moderate to advanced fibrosis under accelerated approval.
If your doctor has flagged heart risk, kidney markers, or fatty liver alongside your insulin resistance, semaglutide gives your provider the most defensible clinical backing — and makes insurance approval significantly easier.
Get started for $39, then as low as $74/mo annual plan.
Needles are the blocker → Compare Oral Wegovy vs Foundayo
You now have two real oral GLP-1 options. Neither requires injections. Both improve insulin-resistance markers. They differ in convenience, evidence depth, and cost.
Oral Wegovy (semaglutide tablets)
Approved December 2025 · 16.6% avg weight loss (OASIS 4)
- · Must take on empty stomach with water only
- · Wait 30+ min before food, drink, or other pills
- · $149/mo at starting dose, $299/mo at 25 mg
- · Deepest oral semaglutide evidence base
Foundayo (orforglipron)
FDA-approved April 1, 2026 · 12.4% avg weight loss (ATTAIN-1)
- · Take any time, with or without food
- · No water restrictions
- · $149/mo starting; as low as $25/mo with insurance
- · Non-peptide small molecule — fundamentally different chemistry
Our take: Foundayo’s convenience makes it the easiest on-ramp. Oral Wegovy delivers more weight loss and has a deeper evidence base.
Foundayo from $149/mo. As low as $25/mo with commercial insurance + Lilly savings card.
Is Tirzepatide Better Than Semaglutide for Insulin Resistance?
For most insulin-resistant adults, yes — tirzepatide is the stronger choice. In SURMOUNT-5 (the first head-to-head randomized trial in people with obesity without diabetes), tirzepatide produced 20.2% vs 13.7% mean weight loss at 72 weeks. More importantly for insulin resistance, a Phase 2b post-hoc analysis (JCEM, 2021) found that weight loss explained only 13–21% of the improvement in HOMA-IR — meaning tirzepatide’s insulin-sensitizing effects are substantially weight-loss-independent.
This dual GIP/GLP-1 mechanism is why tirzepatide’s insulin sensitization outruns its weight loss. GIP receptor activation improves beta-cell function independently, reduces visceral fat through lipid metabolism pathways, and modulates glucose-dependent insulin secretion through a different route than GLP-1 alone.
Choose tirzepatide if:
- ✓Maximum insulin-sensitizing push is the goal
- ✓Prediabetes and want to prevent T2D progression
- ✓Significant visceral fat that won't respond to diet
- ✓No established cardiovascular disease, CKD, or MASH
- ✓Want the strongest head-to-head weight-loss outcomes
Choose semaglutide if:
- ✓Established cardiovascular disease or high CV risk
- ✓Chronic kidney disease (CKD) with T2D
- ✓Fatty liver / MASH diagnosis
- ✓Insurance coverage is stronger with FDA-labeled CV indication
- ✓Want the deepest organ-protection label support
What If You Want a Pill Instead of Injections?
The oral GLP-1 category became real in 2026. Two pills now carry FDA weight-management approval, and both show insulin-sensitizing benefits. For readers who have been avoiding GLP-1s because of needles, this section ends that objection.
Foundayo’s convenience advantage is real. Every GLP-1 only works if you actually take it consistently, and oral Wegovy’s empty-stomach requirement has been a known compliance issue with oral semaglutide since its 2019 launch. If you’re the kind of person who will skip doses because the timing is inconvenient, Foundayo removes that friction entirely.
Oral Wegovy’s evidence advantage is also real. Semaglutide has years of real-world data across millions of patients, cardiovascular outcomes trials, and now the MASH indication. Foundayo was FDA-approved on April 1, 2026. The clinical trial data is strong, but the long-term real-world track record doesn’t exist yet.
Foundayo from $149/mo, as low as $25/mo with commercial insurance + Lilly savings card.
Can You Get a GLP-1 for Insulin Resistance Without Diabetes?
Yes — but not typically under the diagnosis “insulin resistance” alone. GLP-1 access is tied to FDA-approved indications, and the qualifying paths work like this:
Path 1: Obesity (BMI ≥ 30)
If your BMI is 30 or higher, you meet the primary FDA-labeled criteria for Wegovy, Zepbound, or Foundayo. No diabetes diagnosis needed. This is the simplest route.
Path 2: Overweight with comorbidity (BMI 27–29.9)
If your BMI is 27 or higher with at least one weight-related comorbidity — prediabetes, hypertension, dyslipidemia, OSA — you qualify. Insulin resistance itself, if documented with elevated HOMA-IR or fasting insulin, strengthens the case as a comorbidity. Bring lab results to your provider visit.
Path 3: Type 2 diabetes
If your insulin resistance has progressed to T2D, Ozempic and Mounjaro are FDA-approved for that indication and insurance coverage becomes significantly easier.
Why insurance denials happen — and what to do. Most denials happen because the documentation doesn’t match the insurer’s criteria, not because you don’t qualify. Common reasons: BMI not documented in recent visit notes, comorbidity not listed as a diagnosis code, or prior authorization wasn’t filed. Our How to Get Insurance to Cover GLP-1 guide walks through the appeals process.
The cash-pay option if insurance isn’t working. If you’re paying out of pocket, you don’t need to meet insurer criteria — just the prescribing provider’s medical judgment. This is where telehealth providers remove the friction.
Ro handles prior authorization — takes 5 minutes to get started.
Is an FDA-Approved GLP-1 Better Than a Compounded Option for Insulin Resistance?
If your priority is the strongest evidence chain, the clearest safety and quality controls, and the broadest label-backed protection, yes — FDA-approved brand-name medications are the stronger path.
Compounded GLP-1 medications are prepared by licensed pharmacies under federal compounding frameworks (503A for patient-specific prescriptions or 503B outsourcing facilities). They are not FDA-approved as finished products and have not gone through the same clinical trial process.
When Compounded Makes Sense
Compounded routes still serve a real function for readers who:
- Cannot afford brand-name pricing and don’t have insurance coverage
- Live in areas with limited brand-name availability
- Have documented medical needs for different dosing or formulations
If you go the compounded route, verify: the telehealth platform holds LegitScript certification, medications ship from a properly licensed pharmacy, and they arrive with clear lot numbers, expiration dates, and proper temperature handling.
When You Should Not Take the Compounded Route
For a detailed breakdown of where compounding stands right now: Is Compounded GLP-1 Still Available in 2026? →
What Does the Best GLP-1 for Insulin Resistance Cost in 2026?
The price gap ranges from $25/month to over $1,300/month depending on the medication, your dose, your insurance, and the access route. That spread is wide enough to change which medication is actually “best” for your situation.
FDA-Approved Brand-Name Pricing (Verified April 2026)
| Medication | Self-pay: starting dose | Self-pay: maintenance | With insurance | Notes |
|---|---|---|---|---|
| Foundayo (orforglipron pill) | $149/mo (0.8 mg) | $199–$299/mo | As low as $25/mo w/Lilly savings card | Any time, no food restrictions |
| Oral Wegovy (semaglutide pill) | $149/mo (1.5–4 mg) | $299/mo (25 mg) | Varies | Empty-stomach rule applies |
| Zepbound (tirzepatide injection) | $299/mo (2.5 mg vials) | $399–$449/mo (5–15 mg) | Varies; savings card available | Strongest IR data |
| Wegovy injection | $199 intro | $349+/mo | Varies; NovoCare card available | Deepest organ labels |
| Ozempic (semaglutide for T2D) | $199 intro | $349+/mo | Often covered for T2D | T2D indication only |
Sources: Lilly investor relations (April 2026), NovoCare pricing page, Ro pricing page. All verified April 7–11, 2026. Prices are dose-dependent — most patients titrate to higher doses over 2–4 months.
Cash-Pay Compounded Pricing (For Readers Without Insurance Coverage)
| Provider | Medication | Starting price | Ongoing price | Notes |
|---|---|---|---|---|
| MEDVi | Compounded semaglutide injection | $179 first mo | $299/mo | No membership fee, includes consultation |
| MEDVi | Compounded tirzepatide injection | $349/mo | $399/mo | No membership fee, includes consultation |
| Eden | Compounded semaglutide injection | $129 first mo | Varies | $129 intro tied to 3-month plan commitment |
| Eden | Compounded tirzepatide injection | $249 first mo | $329/mo ongoing | Same price at every dose |
| TrimRX | Compounded semaglutide injection | ~$199/mo | ~$199/mo | Flat pricing |
| SkinnyRX | Compounded semaglutide injection | ~$199/mo | ~$199/mo | HSA/FSA cards accepted |
Compounded medications are not FDA-approved as finished products. Pricing verified from provider websites April 7–11, 2026. Some introductory prices require multi-month commitments — check terms before enrolling.
The RX Index Provider Transparency Check (April 2026)
| Factor | Ro | MEDVi | Eden |
|---|---|---|---|
| Starting price publicly listed? | Yes | Yes | Yes |
| Dose-escalation pricing clear? | Yes | Flat rate regardless of dose | Varies — confirm before enrolling |
| Public state availability list? | Yes (all 50 states) | Not published — contact CS | Not fully published |
| Cancellation policy public? | Yes | Yes — 72 hrs before billing, no refund except narrow cases | Varies by plan |
| Price includes medication? | No — membership + medication separate | Yes — all-inclusive | Yes — typically all-inclusive |
| LegitScript certified? | Yes | Yes | Yes |
Important: Compounded pricing typically includes medication and provider consultation in one price. Brand-name pricing through Ro includes the membership fee plus the medication cost separately. Make sure you’re comparing total monthly cost, not just the headline number.
Get started for $39. Insurance concierge handles prior authorization.
Compounded semaglutide from $179/mo first month. No membership fee. LegitScript certified.
Compounded tirzepatide from $249/mo first month. Same price at every dose.
How Do You Know If You Have Insulin Resistance?
The most common clinical method is the HOMA-IR calculation: fasting insulin (µIU/mL) × fasting glucose (mg/dL) ÷ 405. Many clinicians use a HOMA-IR above 2.0–2.5 as a working threshold for insulin resistance, though no universal cutoff exists. Other signs your provider may look for:
- Elevated fasting insulin above 10–15 µIU/mL
- A1C in the prediabetic range of 5.7–6.4%
- Stubborn visceral fat that won’t respond to diet and exercise
- Skin tags or acanthosis nigricans (darkened, velvety skin patches on neck, underarms, or groin)
- PCOS diagnosis (approximately 70% of women with PCOS have insulin resistance)
- Family history of type 2 diabetes
Why this matters for GLP-1 treatment: If your fasting insulin is elevated and your HOMA-IR is above 2.0, that’s strong supporting evidence for a GLP-1 prescription through the overweight-with-comorbidity pathway (BMI ≥ 27). Bring these numbers to your provider visit or telehealth consultation — they strengthen your case for both a prescription and insurance coverage.
Related condition pages:
Frequently Asked Questions
Does tirzepatide reverse insulin resistance?
Tirzepatide significantly improves insulin-resistance markers including HOMA-IR, fasting insulin, and visceral fat in clinical trials. The SURMOUNT-1 three-year extension showed a 94% reduction in progression from prediabetes to type 2 diabetes. Whether this constitutes full reversal depends on sustained treatment and lifestyle changes — improvements tend to diminish after discontinuation.
Is tirzepatide better than semaglutide for insulin resistance?
For most insulin-resistant adults, yes. In a tirzepatide Phase 2b analysis (JCEM, 2021), weight loss explained only 13–21% of the improvement in HOMA-IR — suggesting substantial weight-loss-independent insulin-sensitizing effects. Semaglutide wins when cardiovascular, kidney, or fatty-liver label support is the top priority.
Can you get a GLP-1 for insulin resistance without diabetes?
Yes. No GLP-1 is FDA-approved specifically for insulin resistance, but you can qualify through obesity (BMI 30 or higher) or overweight-with-comorbidity (BMI 27 or higher with a condition like prediabetes, high blood pressure, or high cholesterol) indications. Wegovy, Zepbound, and Foundayo all carry these FDA-labeled weight-management indications.
Is there a GLP-1 pill for insulin resistance and weight loss?
Yes. Two oral GLP-1 options are available in 2026. Foundayo (orforglipron), FDA-approved April 1, 2026, can be taken any time of day without food or water restrictions and starts at $149 per month at the lowest dose. Oral Wegovy (semaglutide tablets), approved December 2025, also starts at $149 per month at lower doses but must be taken on an empty stomach with a 30-minute wait before food.
What is the cheapest GLP-1 for insulin resistance in 2026?
Both Foundayo and oral Wegovy start at $149 per month at their lowest doses for self-pay patients. Foundayo can be as low as $25 per month with commercial insurance and a Lilly savings card. Cash-pay compounded semaglutide starts around $129 per month through some providers on multi-month plans, though compounded medications are not FDA-approved as finished products.
What is the best GLP-1 for prediabetes?
Tirzepatide has the strongest prediabetes-specific data. The three-year SURMOUNT-1 extension showed a 94% reduction in progression from prediabetes to type 2 diabetes in adults with obesity or overweight. No other GLP-1 has published comparable prediabetes-progression outcomes.
What is the best GLP-1 for PCOS and insulin resistance?
Tirzepatide shows the strongest early evidence for PCOS due to its dual GIP/GLP-1 receptor activation and visceral fat reduction. A meta-analysis of 8 randomized trials found GLP-1 receptor agonists superior to metformin for improving insulin sensitivity and reducing BMI in women with PCOS.
What is the best GLP-1 if I have fatty liver (MASH)?
Semaglutide. Wegovy holds an accelerated FDA approval for noncirrhotic MASH with moderate to advanced liver fibrosis — the only GLP-1 with this indication. A Frontiers in Endocrinology meta-analysis also found GLP-1 RAs effectively improve insulin resistance in NAFLD, while SGLT-2 inhibitors showed no apparent effect.
Can insurance cover a GLP-1 for insulin resistance?
Not under insulin resistance alone, but typically yes under obesity or overweight-with-comorbidity diagnoses. The Medicare GLP-1 Bridge program starting July 2026 may cover Wegovy or Zepbound at $50 per month for eligible Part D beneficiaries.
What happens when you stop GLP-1 treatment?
Most studies show significant weight regain within 12 months. The STEP 1 extension trial found approximately two-thirds of lost weight was regained within one year. Insulin-resistance markers typically worsen alongside the weight regain. Sustained lifestyle changes during treatment reduce the degree of rebound.
How do I know if I have insulin resistance?
The most common clinical method is the HOMA-IR calculation: fasting insulin (µIU/mL) multiplied by fasting glucose (mg/dL), divided by 405. Many clinicians use a HOMA-IR above 2.0–2.5 as a working threshold for insulin resistance, though no universal cutoff exists. Other signs include elevated fasting insulin above 10–15 µIU/mL, A1C in the prediabetic range of 5.7–6.4%, stubborn visceral fat, and skin tags or acanthosis nigricans.
Are compounded GLP-1s safe in 2026?
Compounded GLP-1 medications from properly licensed pharmacies (either 503A or 503B facilities operating within their legal framework) can be a reasonable access option. The FDA has flagged quality concerns in some compounded products. Verify your provider has LegitScript certification, the pharmacy is properly licensed, and medications arrive with clear lot numbers and proper storage. Compounded medications are not FDA-approved as finished products.
Still Not Sure Which GLP-1 Program Is Right for You?
Take our free 60-second matching quiz. Answer a few questions about your health situation, insurance status, needle preference, and budget — and get a personalized recommendation for the medication path and provider that fits your specific insulin-resistance pattern. No email required.
→ Take the Free 60-Second Matching QuizThe RX Index is an independent comparison resource for GLP-1 telehealth providers. This page is updated monthly. All pricing, availability, and clinical claims were verified between April 7–11, 2026 using manufacturer sites, FDA labels, published clinical trials, and provider pricing pages. This content is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription treatments requiring evaluation by a licensed healthcare provider. Compounded medications referenced are not FDA-approved as finished products. Last verified: April 11, 2026.
Related guides: Best GLP-1 Online Programs · Best GLP-1 for PCOS · Cheapest GLP-1 Without Insurance · Ro GLP-1 Review · MEDVi Review · Eden Review · Is Compounded GLP-1 Still Available?